Qiagen (NYSE:QGEN) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its holdings in shares of Qiagen (NYSE:QGEN) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,337 shares of the company’s stock after acquiring an additional 2,165 shares during the period. Squarepoint Ops LLC’s holdings in Qiagen were worth $2,849,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. CWM LLC grew its stake in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares during the period. Eagle Asset Management Inc. raised its stake in Qiagen by 2.2% during the 4th quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock worth $883,000 after acquiring an additional 430 shares in the last quarter. TD Asset Management Inc raised its stake in Qiagen by 1.0% during the 4th quarter. TD Asset Management Inc now owns 53,531 shares of the company’s stock worth $2,330,000 after acquiring an additional 554 shares in the last quarter. Riverview Trust Co acquired a new stake in Qiagen during the 1st quarter worth $28,000. Finally, Park Place Capital Corp acquired a new stake in Qiagen during the 1st quarter worth $36,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Qiagen stock opened at $44.35 on Thursday. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The firm has a 50 day moving average price of $45.33 and a 200 day moving average price of $43.49. The company has a market cap of $10.12 billion, a price-to-earnings ratio of 29.74, a PEG ratio of 3.23 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. During the same period in the previous year, the firm earned $0.53 earnings per share. Qiagen’s revenue for the quarter was down .2% on a year-over-year basis. Sell-side analysts predict that Qiagen will post 2.15 earnings per share for the current year.

Analyst Ratings Changes

QGEN has been the topic of several research reports. Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.25.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.